Lisata Therapeutics LSTA

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative therapies for solid tumors and other serious diseases. Its primary investigational product, certepetide, activates the company activates the C-end rule active transport mechanism to improve the delivery of anti-cancer drugs into tumors while sparing healthy tissue. Certepetide also modifies the tumor microenvironment to enhance immune response and inhibit metastasis, supporting combination with various anti-cancer agents. The company operates globally with research and clinical trial activities conducted in collaboration with academic institutions and pharmaceutical partners.

Lisata Therapeutics, Inc. generates revenue primarily through potential future sales of its drug candidates, licensing agreements, and collaborations with pharmaceutical and biotechnology firms. The company currently does not have any approved products on the market, so its revenue is derived from upfront payments, milestone payments, and royalties under research and development partnerships. These collaborations often involve co-development of certepetide with chemotherapy, immunotherapy, or RNA-based therapies for solid tumor indications. Revenue is also supported by government and private grants for preclinical and clinical research activities.

Lisata Therapeutics, Inc. operates through a single business segment dedicated to the development of its CendR Platform® and associated product candidates.

• CendR Platform®: This segment focuses on the discovery and development of certepetide and other molecules that activate the C-end rule active transport mechanism to enhance tumor-specific drug delivery. The platform enables improved penetration of co-administered anti-cancer therapies such as chemotherapeutics, immunotherapies, and antibody-drug conjugates into solid tumors. Certepetide, as the lead product from this platform, is a proprietary internalizing RGD peptide designed to bind integrins and neuropilin-1 to facilitate drug uptake in tumor tissues. The company holds trademarks for CendR Platform® and continues to expand its intellectual property portfolio through pending patent applications in the United States and abroad covering methods of tumor reduction and combination therapies.

Lisata Therapeutics, Inc. operates in the highly competitive oncology therapeutics industry, where it differentiates itself through its novel CendR® mechanism that improves drug delivery without creating new chemical entities initially. The company faces competition from other biotech firms developing tumor-penetrating agents, antibody-drug conjugates, and immunotherapy combinations, but holds a distinct position due to its mechanistic approach to enhancing existing therapies. Its competitive advantage lies in the ability to potentially increase efficacy of standard-of-care treatments while maintaining a favorable safety profile, as demonstrated in clinical trials for metastatic pancreatic cancer.

Lisata Therapeutics, Inc. serves patients with solid tumors, particularly those with metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, glioblastoma, and other aggressive cancers. The company collaborates with hospitals, cancer treatment centers, academic research institutions, and clinical trial networks to advance its therapies. Specific customer or collaborator names referenced in the filing include the Australasian Gastrointestinal Clinical Trials Group, the University of Sydney, Qilu Pharmaceutical, and Catalent, with whom it has conducted or supported clinical development activities.